The objectives of the LEGATO Project in the words of Principal Investigator and Co-Leader Prof. Dr Matthias Preusser
LEGATO is part of a series of clinical trials funded by the Horizon Europe programme as part of...
The LEGATO project is proposing an investigator-initiated phase III randomised pragmatic clinical trial.
Recurrent glioblastoma is an invariably fatal refractory cancer with dismal prognosis. Patients suffer from low quality of life and very burdensome symptoms.
Cost-effectiveness analysis will be performed to investigate the economic value of adding radiation treatment to lomustine chemotherapy.
We are a multidisciplinary and multistakeholder consortium involving clinical oncologists, radiation oncologists, health economists and patient representatives. The study design was successfully discussed with patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment.”
LEGATO is part of a series of clinical trials funded by the Horizon Europe programme as part of...
Over the last couple of months, we introduced the people and organisations behind the LEGATO Project on our...
The European Organisation for Research and Treatment of Cancer (EORTC) and the Syreon Research Institute are delighted to...
© The LEGATO Consortium 2023-2028. This project has received funding from the European Union’s HORIZON-MISS-CANCER-2022-01 under grant agreement Nº (101103655). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
Copyright © 2024 All rights reserved.